Evidence map›Paper›PMID 37059469›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2023

High and Persistent Anti-GM1 Antibody Titers Are Associated With Poor Clinical Recovery in Guillain-Barré Syndrome.

Robin C M Thomma, Christiaan Fokke, Christa Walgaard, Denise M C Vermeulen-de Jongh, Anne Tio-Gillen, Wouter van Rijs, Pieter A van Doorn, Ruth Huizinga, Bart C Jacobs

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Gangliosides and Autoimmune Neuropathies.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Guillain-Barré syndrome.Nature reviews. Disease primers · 2024
    Article
  14. Guillain-Barré syndrome: a comprehensive review.European journal of neurology · 2024
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robin C M ThommaFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.ORCID 0000-0001-5584-2457
Christiaan FokkeFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Christa WalgaardFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Denise M C Vermeulen-de JonghFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Anne Tio-GillenFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Wouter van RijsFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Pieter A van DoornFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Ruth HuizingaFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands.ORCID 0000-0002-9563-4860
Bart C JacobsFrom the Department of Neurology (R.C.M.T., C.F., C.W., A.T.-G., W.R., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Immunology (R.C.M.T., D.M.C.V.-J., A.T.-G., W.R., R.H., B.C.J.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (C.F.), Gelre Hospital, Apeldoorn; Department of Neurology (C.W.), IJsselland Hospital, Capelle aan den IJssel; and Department of Hematology (D.M.C.V.-J.), Erasmus MC, University Medical Center Rotterdam, The Netherlands. b.jacobs@erasmusmc.nl.ORCID 0000-0002-8985-2458
Gelre Hospitals · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesGuillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that may follow a preceding infection inducing a cross-reactive antibody response to glycosphingolipids in peripheral nerves. The immune response in GBS is considered to be short lasting, explaining its monophasic clinical course. However, the disease course varies between patients, and residual deficits frequently occur. The duration of the antibody response has not been defined extensively in GBS, and the persistence of these antibodies may impair clinical recovery. The aim of this study was to determine the titer course of serum antibody titers to the ganglioside GM1 in relation to clinical course and outcome in patients with GBS.

methodsAcute-phase sera from patients with GBS included in previous therapeutic trials were screened for anti-GM1 IgG and IgM antibodies in ELISA. Anti-GM1 antibody titers were determined in sera collected at entry and during a 6-month follow-up. Clinical course and outcomes were compared between groups based on the titer course.

resultsAnti-GM1 antibodies were detected in 78 (20.7%) of 377 included patients. The anti-GM1 IgG and IgM antibody titer course was highly variable between patients. A subset of anti-GM1-positive patients had persistent anti-GM1 antibodies at 3 months (n = 27/43 [62.8%]) and 6 months (n = 19/41 [46.3%]). Patients with a high anti-GM1 IgG and IgM titer at entry recovered more slowly and less complete than anti-GM1-negative patients (IgG: DISCUSSION: High anti-GM1 IgG and IgM antibody titers at entry and persistent high anti-GM1 IgG antibody titers are associated with poor outcome in patients with GBS. Antibody persistency indicates ongoing antibody production long after the acute disease state in GBS. Further research is required to determine whether antibody persistency interferes with nerve recovery and is a target for treatments.

Indexed as

Guillain-Barre SyndromeDisease ProgressionG(M1) GangliosideHumansImmunoglobulin GImmunoglobulin MG(M1) GangliosideImmunoglobulin GImmunoglobulin M

Identifiers

PMID37059469
PMCPMC10119811
OpenAlexW4365810859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.